Purdue Pharma has patented a parenteral formulation containing nalmefene or its salt and magnesium chloride adjuvant, allowing rapid absorption for opioid overdose treatment. The formulation provides opioid antagonistic action within 5 minutes post-injection. GlobalData’s report on Purdue Pharma gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Premium Insights Purdue Pharma LP - Company Profile

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Purdue Pharma, Human telomerase RT biomarker was a key innovation area identified from patents. Purdue Pharma's grant share as of January 2024 was 51%. Grant share is based on the ratio of number of grants to total number of patents.

Parenteral formulation for rapid opioid overdose treatment

Source: United States Patent and Trademark Office (USPTO). Credit: Purdue Pharma LP

A recently granted patent (Publication Number: US11865112B2) discloses a parenteral formulation designed to provide rapid opioid antagonistic action in cases of opioid agonist overdose. The formulation includes nalmefene or its salt and magnesium chloride as an adjuvant, with a concentration ranging from 0.5% to 1%. Administered via intramuscular or subcutaneous injection, the formulation aims to achieve an onset of action in less than 5 minutes post-administration, offering a potentially life-saving intervention for individuals experiencing opioid overdose.

Furthermore, the patent claims detail specific parameters for the parenteral formulation, including mean time to maximum plasma concentration of nalmefene post-injection in healthy subjects, as well as the time to clinically manifested onset of opioid antagonistic action. The inclusion of magnesium chloride in the formulation is highlighted for its role in promoting systemic absorption rates and total amount absorbed compared to formulations without the adjuvant. Additionally, the patent outlines methods for providing opioid overdose rescue and preparing individuals for potential opioid exposure using the disclosed formulation, emphasizing the importance of rapid action and effective delivery mechanisms such as pre-filled syringes or auto-injectors.

To know more about GlobalData’s detailed insights on Purdue Pharma, buy the report here.

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies